Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenapanor Phase 2b in Hyperphosphatemia
NCT02081534Phase 2Completed
- Sponsor
- Ardelyx
- Start
- Mar 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of tenapanor in hyperphosphatemia (7 arms), sponsored by Ardelyx. Primary endpoint: Change in Serum Phosphate Levels at Day 29. Started Mar 2014; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT02081534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081534.